Cancer Management and Research
Volume 13, 2021 - Issue
Original Research
Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
, , 
, , &
Maobai Liu2 Department of Pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, Fujian Province, People’s Republic of Chinahttps://orcid.org/0000-0002-8382-7868
https://orcid.org/0000-0002-8382-7868, , & Hongfu Cai2 Department of Pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, Fujian Province, People’s Republic of ChinaCorrespondence[email protected] [email protected]
https://orcid.org/0000-0002-4923-4882
https://orcid.org/0000-0002-4923-4882